Mitchell Capital Management Co. Sells 266 Shares of Eli Lilly and Company (NYSE:LLY)

Mitchell Capital Management Co. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,637 shares of the company’s stock after selling 266 shares during the quarter. Eli Lilly and Company accounts for about 1.6% of Mitchell Capital Management Co.’s investment portfolio, making the stock its 14th largest position. Mitchell Capital Management Co.’s holdings in Eli Lilly and Company were worth $8,983,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Values Added Financial LLC lifted its position in shares of Eli Lilly and Company by 4.9% during the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after buying an additional 17 shares during the period. Pursue Wealth Partners LLC bought a new position in Eli Lilly and Company in the 3rd quarter valued at $364,000. Creative Financial Designs Inc. ADV raised its position in Eli Lilly and Company by 2.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 16,339 shares of the company’s stock valued at $14,475,000 after purchasing an additional 325 shares during the last quarter. Lebenthal Global Advisors LLC raised its position in Eli Lilly and Company by 12.6% in the 3rd quarter. Lebenthal Global Advisors LLC now owns 2,177 shares of the company’s stock valued at $1,929,000 after purchasing an additional 243 shares during the last quarter. Finally, Interchange Capital Partners LLC raised its position in Eli Lilly and Company by 2.2% in the 3rd quarter. Interchange Capital Partners LLC now owns 1,061 shares of the company’s stock valued at $940,000 after purchasing an additional 23 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.7 %

Shares of Eli Lilly and Company stock opened at $920.44 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The business has a fifty day simple moving average of $814.88 and a 200 day simple moving average of $848.69. The stock has a market cap of $872.73 billion, a PE ratio of 78.60, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has initiated a share repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s payout ratio is 51.24%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Bank of America reiterated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Wells Fargo & Company cut their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.